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BRAFV600E mutation is highly 
prevalent in thyroid carcinomas 
in the young population in 
Fukushima: a different oncogenic 
profile from Chernobyl
Norisato Mitsutake1,4,*, Toshihiko Fukushima5,*, Michiko Matsuse1,*, Tatiana Rogounovitch3, 
Vladimir Saenko2, Shinya Uchino7, Masahiro Ito6, Keiji Suzuki1, Shinichi Suzuki5,§ & 
Shunichi Yamashita1,2,§
After the accident at the Fukushima Daiichi Nuclear Power Plant, the thyroid ultrasound screening 
program for children aged 0–18 at the time of the accident was started from October 2011. The 
prevalence of thyroid carcinomas in that population has appeared to be very high (84 cases per 
296,253). To clarify the pathogenesis, we investigated the presence of driver mutations in these 
tumours. 61 classic papillary thyroid carcinomas (PTCs), two follicular variant PTCs, four cribriform-
morular variant PTCs and one poorly-differentiated thyroid carcinoma were analysed. We detected 
BRAFV600E in 43 cases (63.2%), RET/PTC1 in six (8.8%), RET/PTC3 in one (1.5%) and ETV6/NTRK3 in 
four (5.9%). Among classic and follicular variant PTCs, BRAFV600E was significantly associated with 
the smaller size. The genetic pattern was completely different from post-Chernobyl PTCs, suggesting 
non-radiogenic etiology of these cancers. This is the first study demonstrating the oncogene profile in 
the thyroid cancers discovered by large mass screening, which probably reflects genetic status of all 
sporadic and latent tumours in the young Japanese population. It is assumed that BRAFV600E may not 
confer growth advantage on paediatric PTCs, and many of these cases grow slowly, suggesting that 
additional factors may be important for tumour progression in paediatric PTCs.
After the accident at the Fukushima Daiichi Nuclear Power Plant due to the Great East Japan Earthquake 
occurred on March 11th, 2011, there have been great concerns regarding a possible health impact by radi-
oactive materials released into the environment. Fukushima prefecture, therefore, started the Fukushima 
Health Management Survey for long-term health management1,2. This survey includes the thyroid ultra-
sound screening program for all children aged 0–18 years old at the time of the accident. After the 
Chernobyl accident, internal exposure to radioactive iodine induced a massive increase in childhood 
thyroid cancers in Belarus, Ukraine and Russia3–6. This increase started to appear 4–5 years after the 
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accident. Therefore, the first round of the screening program, so-called the baseline survey, was started 
in October, 2011 to grasp the general ultrasound findings in children and adolescents, because such a 
screening program for a huge number of young individuals using advanced ultrasound technologies has 
never been done. After the first round of the screening, the prevalence of thyroid cancers in Fukushima 
appeared to be quite high: 84 per 296,253 children as of October 2014 (http://www.fmu.ac.jp/radia-
tionhealth/results/media/17-2_Thyroid_Ultrasound_Examination_I-S.pdf). Most of them were papillary 
thyroid carcinomas (PTCs). Logically, this increase has been thought to be due to screening effect with 
advances in diagnostic instruments in recent years, because the estimated thyroid doses of radioiodine 
exposure in Fukushima were far lower than those in Chernobyl7–9, and the period from the date of the 
accident until the onset is too short. Presumably, a real morbidity rate may be comparable throughout 
Japan10,11, and many of the PTC cases could be silent or very slowly progressing until middle or older age.
PTCs have particular genetic alterations such as RET/PTC rearrangements and point mutations in 
the BRAF and RAS family genes resulting in activation of the mitogen-activated protein kinase (MAPK) 
pathway12,13. There are more than 15 different types of RET/PTC chimeric genes that differ according 
to the 5’ partner gene involved in the rearrangement. RET/PTC1 and RET/PTC3 are the most common 
types, accounting for more than 90% of all the rearrangements. These oncogenes rarely overlap in a same 
tumour, providing strong genetic evidence for the requirement of constitutive active MAPK signaling 
for the development of PTC. In adult sporadic PTCs, the BRAFV600E mutation is the most prevalent 
genetic alteration ranging approximately 30–70%14–18. On the other hand, the RET/PTC rearrangements 
have been reported to be dominant in childhood sporadic PTCs19,20. Regarding radiation-induced thy-
roid carcinomas, post-Chernobyl PTCs also had higher prevalence of the RET/PTC rearrangements. 
Especially, in cases with short latency (developed less than 7–10 years after the accident), they were 
found in 64–86% of the tumours, and RET/PTC3 was the most frequent type of the rearrangement in 
this group5. Consequently, the pattern of genetic alterations in PTCs depends on patient age and etiology 
of the tumours.
In the present study, we investigated the presence of various known genetic alterations in 68 operated 
cases discovered in Fukushima. First, we aimed to assess whether their genetic pattern is similar to that 
of post-Chernobyl PTCs, even though these Fukushima cases are very unlikely to be radiation-induced. 
Second, we also attempted to gain insight into the carcinogenic mechanisms of the thyroid cancers found 
by the large mass screening program in the young population in Fukushima.
Results
The profile of the genetic alterations. We obtained tissue samples from 68 patients operated at 
Fukushima Medical University, consisting of 61 classical PTCs, two follicular variant PTCs, four cribri-
form-morular variant PTCs and one poorly differentiated thyroid carcinoma (PDTC). We first screened 
them for BRAF (exon 15), HRAS, KRAS and NRAS (codons 12, 13 and 61), and RET/PTC1 and RET/
PTC3. In samples without above-mentioned frequent known genetic alterations, we next investigated 
the presence of AKAP9/BRAF and ETV6(exons 4 and 5)/NTRK3 rearrangements. The mutation in the 
TERT promoter (C250T and C228T) was checked in all samples. The clinicopathological features and 
genotyping results are summarized in Table 1 and 2, respectively. We found these known oncogenes in 
54 out of 68 (79.4%) samples. The BRAFV600E mutation was highly prevalent and found in 43 out of 68 
(63.2%). Note that four cases showed the weak signal of a mutant allele: the intensity of A signal in the 
sequence chromatogram was less than 20% compared to that of T signal (Table 1). In these tumours, the 
BRAFV600E mutation may not be clonal. None of samples had the RAS mutation nor the TERT promoter 
mutation. Regarding the fusion genes, six RET/PTC1, one RET/PTC3 and four ETV6(ex.4)/NTRK3 were 
detected. AKAP9/BRAF and ETV6(ex.5)/NTRK3 were not found. In one PDTC, we did not find any of 
the above genetic alterations. The four cases with cribriform-morular variant PTCs are highly suspected 
to be familial adenomatous polyposis; the analyses of the APC gene/genetic counseling are being con-
ducted, and their results will be published elsewhere.
Clinicopathological correlations. We compared clinicopathological parameters between the 
BRAFV600E mutation-positive PTC cases and the BRAFV600E-negative PTCs including the fusion 
gene-positive and mutation-negative cases, excluding cribriform-morular PTCs. As shown in Table  3, 
the BRAFV600E mutation was significantly associated with smaller tumour size (12.2 ± 6.8 mm in the 
BRAFV600E-positive PTCs vs. 18.3 ± 9.5 mm in the BRAFV600E-negative PTCs) but not with the TNM 
parameters and extrathyroidal extension in univariate analysis. On multivariate analysis adjusted for age 
and sex, tumour size in BRAFV600E-positive cases was still significantly smaller than that in the negative 
cases (Table  3), and also an association with older patients’ age was detected after adjustment for sex 
(Table 3).
Discussion
In the present study, we have demonstrated that high prevalence of the BRAFV600E mutation and low 
frequency of chromosomal rearrangements such as RET/PTC in young PTC cases were found by the 
screening program. There are not so many publications about the BRAF mutation in paediatric thy-
roid carcinomas. In the early period (2004–2005) after the discovery of the BRAF mutation in thyroid 
cancers, its prevalence in paediatric PTCs was reported to be 0–20%21–24. However, two very recent 
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papers published in 2014 demonstrated much higher prevalence (63 and 36.8%, respectively), especially 
in tumours with classic papillary subtype (71.4 and 63.6%, respectively)25,26. We cannot explain this 
discrepancy although all of these studies analysed a limited number of cases. One possibility is that this 
increase may be due to improved sensitivity of detection methods: PCR-restriction fragment length pol-
ymorphism (RFLP) and pyrosequencing were used in the recent studies. As the histological classification 
of most of our Fukushima cases was classic papillary subtype, our data are consistent with the recent 
studies. The prevalence of the BRAFV600E mutation depends on population and iodine intake27. In East 
Asian countries such as South Korea and Japan where iodine intake is very high, PTCs usually show very 
high rate of the BRAFV600E mutation. Our cases in Fukushima demonstrated a similar rate. In terms of 
the BRAF mutation in radiation-induced paediatric thyroid carcinomas including post-Chernobyl PTCs, 
its prevalence was reported to be low (0–17%)5,21,28. Furthermore, point mutations have been shown to 
Age at operation (ave, y.o. ± s.d.) 17.3 ± 2.8






















Table 1. Clinicopathological features of the current cases. CP: classic papillary, FV: follicular variant, 












Table 2. Genetic alterations in the current cases. *including 4 cases in which the strength of A signal in 
the sequence chromatogram was less than 20% compared to that of T signal.
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display negative dose-response relationship in thyroid cancers in Chernobyl29 and in A-bomb survivors30. 
These observations are suggestive of non-radiogenic etiology of the thyroid cancers in Fukushima.
In the post-Chernobyl paediatric PTCs, the RET/PTC rearrangements were usually detected in more 
than 50%. RET/PTC3 was the most common type in tumours with short latency (4–8 years after the 
exposure), whereas tumours developed after longer period of time had RET/PTC1 predominantly. In 
addition, RET/PTC3 had a strong correlation with solid variant subtype, while RET/PTC1 usually found 
in classic papillary subtype5. Ricarte-Filho et al.31 reported the results of analysis of driver mutations in 
post-Chernobyl radiation-exposed PTCs that showed a similar age range to our series (radiation-exposed, 
median: 17.8 years old, range: 13.4–23.0; Fukushima, median: 18.0 years old, range: 9–22). In this report, 
the prevalence of the RET/PTC rearrangements in the radiation-exposed cases was 57.7%. The detected 
rate of the RET/PTC rearrangements in our series was only 10.3%, all of which were RET/PTC1 except 
one RET/PTC3, also suggesting that the mode of carcinogenesis in the Fukushima cases is different from 
post-Chernobyl PTCs.
The prevalence of the RET/PTC rearrangements in sporadic paediatric PTCs was reported to be also 
high (30–67%)5,19. In the above paper by Ricarte-Filho et al.31, sporadic PTCs, most of which were teen-
agers (median: 16.6 years old, range 5.8–19.8), were also analysed, and the prevalence of the RET/PTC 
rearrangements was 25.9%. As far as we are aware, there are only two studies that analysed Japanese 




Univariate p-value; OR 
(95% CI)
Multivariate p-value; OR or B 
(95% CI)
All PTC cases 43 20
Age at operation 
(y.o. ± s.d.) 18.2 ± 2.3 16.7 ± 3.7 0.115
a 0.041; B = 1.629 (0.068–3.190)c
Sex 0.155
b; OR = 2.880 (0.823–
10.076) 0.089; OR = 3.115 (0.841–11.494)
e
 M 18 4
 F 25 16
Tumor size 
(mm ± s.d.) 12.2 ± 6.8 18.3 ± 9.5 0.002
a 0.005; B = -6.547 (−11.060–
−2.034)d
Microcarcinoma 0.012
b; OR = 5.937(1.515–
23.260) 0.037; OR = 4.477 (1.095–18.303)
f
 ≤ 10 mm 22 3
 > 10 mm 21 17
Histology 0.097
b; OR = 11.757(0.537–
257.210)
Not performed because of no FV in 
the BRAFV600E group
 CP 43 18
 FV 0 2
pT 0.103
b; OR = 2.840(0.942–
8.566) 0.086; OR = 2.779 (0.866–8.923)
f
 pT1 or 2 26 7
 pT3 17 13
pN 0.714
b; OR = 0.667(0.165–
2.692) 0.783; OR = 0.800 (0.164–3.917)
f
 pN0 6 4
 pN1a or 1b 36 16
M 0.090
b; OR = 0.080(0.004–
1.764)
Not performed because of no M in 
the BRAFV600E group
 M0 43 17
 M1 0 2
pEx 0.109
b; OR = 0.388(0.129–
1.166) 0.096; OR = 0.370 (0.115–1.193)
f
 pEx0 18 13
 pEx1 25 7
Table 3. Association of the BRAFV600E mutation with clinicopathological features of the PTC cases found 
by mass screening. aMann-Whitney test. bFisher’s exact test. cLinear regression adjusted for sex. dLinear 
regression adjusted for age and sex. eLogistic regression adjusted for age. fLogistic regression adjusted for age 
and sex. OR: odds ratio, B: regression coefficient, CI: confidential interval, CP: classic papillary, FV: follicular 
variant.
www.nature.com/scientificreports/
5Scientific RepoRts | 5:16976 | DOI: 10.1038/srep16976
the cohort in the present study is completely different from those in the above previous studies because 
the data in this work were obtained due to mass screening of basically healthy individuals without any 
symptom. Even though the incidence in Fukushima has been much higher than that reported previously, 
it is quite unlikely that this is due to radiation exposure because of their shorter latency and higher age 
distribution34,35. Moreover, the patterns of the genetic alterations in our cases were completely different 
from radiation-induced PTCs. Assuming that most of these cases would be silent until middle or older 
age, we could speculate that paediatric PTCs with the BRAFV600E mutation may be not so progressive 
compared to those with the rearrangements. Consistent with this hypothesis, our data in the present 
study has demonstrated that tumours with the BRAFV600E mutation were significantly smaller than 
BRAFV600E-negative cases including RET/PTC or ETV6/NTRK3. It is supposed that we detected these 
tumours earlier in life because of the extremely sensitive ultrasound screening procedure.
ETV6/NTRK3 has been recently found in both radiation-associated paediatric PTCs and sporadic 
paediatric PTCs with comparable frequencies (2 of 26 in exposed and 2 of 27 in sporadic)31, although 
the number of analysed cases was limited. It has been reported that this rearrangement was significantly 
more common in post-Chernobyl PTCs (mean age: 22.7 ± 5.1 years; 9 of 62, 14.5%) than in sporadic 
PTCs (mean age: 45.6 ± 17.7 years; 3 of 151, 2%); however, the age was not matched in this study29. Thus, 
the association between ETV6/NTRK3 and radiation exposure is not clear, and this fusion gene may just 
be associated with young age.
TERT promoter mutations (C250T and C228T) have also been discovered recently in thyroid can-
cers36,37. These mutations are highly associated with older age and worse prognosis38,39. Some papers have 
also reported that these mutations are correlated with the presence of the BRAFV600E mutation36,38–40. 
Here we demonstrate that these mutations were completely absent in this age group even though many 
of them carried the BRAFV600E mutation.
In conclusion, the genetic profile of the Fukushima thyroid cancers was completely different from 
post-Chernobyl radiation-induced PTCs, suggesting non-radiogenic etiology of these cancers. However, 
note that since similar high-resolution ultrasound apparatus was not available after the Chernobyl acci-
dent, it might be difficult to strictly compare the results of the two populations. Simultaneously, we for 
the first time demonstrate the distribution of the oncogenes in the young thyroid cancer cases discovered 
by large mass screening. This probably reflects genetic status of all sporadic and latent thyroid carcino-
mas in the young Japanese population. The prevalence of the BRAFV600E mutation was comparable to 
Japanese adult cases, implying that the carcinogenic mechanisms may be similar between paediatric and 
adult PTCs. However, it is assumed that the BRAFV600E mutation may not confer growth advantage on 
paediatric PTCs, and many of these tumours do not grow rapidly, suggesting that additional factors may 
be necessary to enhance tumour growth. Thus, it is beneficial to identify such a key factor to improve 
the management of paediatric PTC patients.
Methods
The thyroid ultrasound screening program under the Fukushima Health Management Survey is being 
conducted by Fukushima Medical University. This program covers all residents in the Fukushima pre-
fecture aged from zero to 18 years old at the time of the accident. During first three years, the baseline 
survey has been conducted. We also included three cases in the same age range incidentally discovered 
through other medical examinations in the same region.
We analysed 68 thyroid cancer cases operated between February 2013 and September 2014 (mean age: 
17.3 years old; mean tumour size: 14.7 mm; 22 males and 46 females) at Fukushima Medical University. 
Fresh tumour tissue samples were obtained during surgical operations, snap-frozen in liquid nitrogen, 
and stored at − 80 °C. DNA and total RNA were extracted at the same time using ISOGEN reagent 
(Nippon Gene) according to the manufacturer’s protocol. Mutations of BRAF (exon 15), HRAS, KRAS 
and NRAS (codons 12, 13 and 61), and TERT promoter (C250T and C228T) were examined by direct 
DNA sequencing. PCR enzymes and primer sequences used for PCR amplifications and sequencing are 
listed in Supplemental Table S1. PCR products were then treated with ExoSAP-IT PCR clean-up rea-
gent (GE Healthcare), and sequencing was performed with Big Dye Terminator sequencing kit version 
3.1 (Applied Biosystems) on an ABI3730 automated sequencer (Applied Biosystems). For RET/PTC, 
AKAP9/BRAF and ETV6/NTRK3 detection, total RNA was reverse transcribed using High Capacity 
RNA-to-cDNA kit (Applied Biosystems). Subsequent PCR amplifications were done using PCR enzymes 
and primers listed in Supplemental Table S1. We included 3–5 negative controls (w/o template) per 96 
samples in every PCR to ensure contamination-free amplifications.
Statistical analysis was performed using the SPSS software version 21.0.0.0 (IBM). Mann-Whitney or 
Fisher’s exact test were used for continuous variables or group analyses, respectively. For multivariate 
analyses, linear or logistic regression models were used. The p value less than 0.05 was regarded as indi-
cating statistical significance.
This study was approved by the ethics committees of Fukushima Medical University and Nagasaki 
University. Written informed consent was obtained from each patient. All experiments were carried out 
in accordance with the approved study plan and relevant guidelines.
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